Varian Stands Firm Against Rival Bid For SirTex; What Next If It All Falls Down?
Executive Summary
Varian Medical Systems' proposed $1.3bn deal to acquire SirTex Medical is officially in jeopardy after China's CDH Investments formalized its rival bid to snatch away the Australian interventional oncology firm. Should the deal fall through, what would Varian's next steps be?
You may also be interested in...
Money Talks Louder To Sirtex As Varian Gets Ditched
Sirtex Medical has accepted the acquisition bid from the owners of CDH Genetech for Aus $33.60 per share, or $1.41bn, that was first announced in May. In January, Varian signed a deal to acquire Sirtex for Aus$28 per share ($1.28bn), but decided not to match CDH's bid, and Sirtex's board decided the higher sale price was worth the additional uncertainties that come with accepting the offer.
M&A Analysis – Acquisitions Come What May
The steady flow of medtech M&A deal-making continued in May; Medtech Insight recorded 16 acquisitions last month, including a global merger of Sivantos and Widex to form the world's third-largest hearing-aid company, ready to challenge market leaders Sonova and William Demant.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.